Phase II trial of dose dense docetaxel followed by FEC100 as neoadjuvant chemotherapy in patients with operable breast cancer.

Abstract

OBJECTIVES The aim of this study was to evaluate the efficacy and safety profile of 4 dose-dense cycles of docetaxel followed by 3 cycles of FEC100 neoadjuvant chemotherapy in patients with operable advanced breast cancer. METHODS Women were treated by 4 cycles of 100 mg/m² docetaxel every 2 weeks, followed by 3 cycles of FEC100 given every 3 weeks. The… (More)
DOI: 10.1097/COC.0b013e3181bead47

Topics

6 Figures and Tables

Cite this paper

@article{Jacot2010PhaseIT, title={Phase II trial of dose dense docetaxel followed by FEC100 as neoadjuvant chemotherapy in patients with operable breast cancer.}, author={William Jacot and Fr{\'e}d{\'e}ric Bibeau and Sophie Gourgou-Bourgade and Marian Gutowski and P L Colombo and Jean-Pierre Bleuse and Andrew Kramar and Gilles H Romieu}, journal={American journal of clinical oncology}, year={2010}, volume={33 6}, pages={544-9} }